PCSK9 brings exorbitant price, and perhaps cost-control consensus

Dave Schafer | | Cardiovascular Business | Economics

Specialty medications have been largely free from cost controls. But the introduction of injectable proprotein convertase subtilisin/kexin 9 (PCSK9) enzyme inhibitors to manage cholesterol—and the sticker shock the drug’s price will bring to consumers—might be the impetus for the healthcare system to develop consensus about the pricing of specialty medications, according to a post on the Health Affairs blog.

In the debate about cost and efficacy, PCSK9 inhibitors may be the biggest chal…

Dave Schafer

Related Content

Eko Health’s AI platform for digital stethoscopes granted new CPT code
Cardiologist demand is on the rise—can hospitals keep up?
Cardiologist receives 35 months in prison for health insurance fraud
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule
Renal denervation systems from Recor Medical, Medtronic receive new outpatient payments
Boston Scientific agrees to acquire AFib ablation company

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Design by Adaptive Theme
Trimed Popup
Trimed Popup